Golan T, et al. - A randomized, double-blind, placebo-controlled, phase 3 trial conducted in patients with germline BRCA1 or BRCA2 mutation and metastatic pancreatic cancer and disease that had not progressed during first-line platinum-based chemotherapy to assess the effectiveness of the poly(adenosine diphosphate–ribose) polymerase (PARP) inhibitor olaparib as maintenance therapy. In a randomly assigned 3:2 ratio, olaparib tablets or placebo were administered to 154 patients. The incidence of grade 3 or higher adverse events was 40% in the olaparib group and 23% in the placebo group. Longer progression-free survival was seen with olaparib as maintenance vs placebo in germline BRCA mutation and metastatic pancreatic cancer patients.